Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Phase 1

• Conditions: Advanced solid tumors; MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2022-000137-17-IT
• Lead Sponsor: BioAtla Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-08-24
• Last Update Posted: 12 March 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 134

Inclusion Criteria

Patients must:
- Have histologically or cytologically confirmed locally advanced unresectable or metastatic NSCLC or melanoma;
- Age > = 18 Year;
- Adequate renal function
- Adequate liver function;
- Adequate hematological function;
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of at least three months

For the full list please see the protocol
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 41
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 93

Exclusion Criteria

- Clinically significant cardiac disease;
- Known non-controlled central nervous system (CNS) metastasis;
- Prior therapy with a conjugated or unconjugated auristatin derivative / vinca-binding site targeting payload;
- A history of allergic reactions to mAb therapy of grade equal to 3 or higher as well as known or suspected allergy or intolerance to any agent given during this study.
- Major surgery within 4 weeks before first BA3011 administration;
- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
- Women who are pregnant or breast feeding

For the full list please see the protocol

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified